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Introduction 
 
During the last century, numerous compounds, such as polychlorinated biphenyls (PCBs) or 
organochlorine pesticides (OCPs), were banned because of their bioaccumulative and toxic 
properties, while other compounds, such as polybrominated diphenyl ethers (PBDEs), appeared on 
the market and consequently in the environment. The experiences gained from accidents involving 
PBBs, PCBs or PCDD/Fs are useful to conduct scientific investigations focused on preventing 
similar catastrophies with the newly introduced compounds. Several studies have reported potential 
increase in  the concentration of PBDEs in food and wildlife. Monitoring the levels of toxic 
chemicals is therefore useful to understand the exposure pathways, sources and trends.  
The aim of the paper is to present actual contamination’s levels of various pollutants in human 
plasma from Belgium. Several classes of pollutants, such PCDD/Fs, PCBs and OCPs were 
determined in 20 human plasmas. In addition, perfluorooctanesulfonate (PFOS) and related 
fluorochemicals, which are of current concern, were measured. Although anticipated, 
concentrations of PBDEs in the same samples were not yet determined. Through this study, a good 
approximation of the contamination level in Belgian human is given, allowing thus comparison 
with concentrations observed in other countries. 
 
Methods and Materials 
 
Sample collection 
Twenty individual plasma samples were collected in 1998 and 2000 by the Belgian Red Cross 
and frozen at -80°C after donation. In 2003, samples were thawed and divided in aliquots 
depending of the amount of plasma needed for the various analyses. All aliquots were stored in PE 
tubes and kept at -20°C until sending to the different laboratories.  
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Of the 20 human blood plasmas, only four samples were given by women. The donors were 
living all over Belgium.  The age range of participants varied from 19 to 63 years, with a mean and 
median of 43.3 and 43.5 years, respectively. The body mass index (BMI) was calculated for 18 
donors for whom information on weight and height were available. Mean and median BMI were 
26.4 and 25.3 kg/m² (range: 19.4-39.9). Only one donor lived near a municipal solid waste 
incinerator. The number of current smokers, ex-smokers and non smokers were of 6, 2 and 12 




Analyses of perfluorooctanesulfonate (PFOS), perfluorooctanoic acid (PFOA) and 
perfluorohexanesulfonate (PFHS) were performed by the Wadsworth Center (Albany, NY, USA). 
These compounds were extracted of the plasma samples using an ion-pairing extraction procedure 
and were determined using an HPLC interfaced with ES-MS/MS. Details on recoveries and limits 
of quantification were previously published1.  
 
Concentration of PCBs and OCPs were determined by the Toxicological Center (Antwerp, 
Belgium). The OCPs under investigation were α-, β-, γ-isomers of hexachlorocyclohexane (HCH), 
o,p´-DDE, p,p´-DDE, o,p´-DDD, p,p´-DDD, o,p´-DDT and p,p´-DDT, octachlorostyrene (OCS), 
hexachlorobenzene (HCB), oxychlordane (OxC), trans-nanochlor (TN), trans-(TC) and cis-
chlordane (CC). The target PCB congeners were PCB 18, 28, 31, 44, 52, 66, 74, 95, 99, 101, 105, 
110, 118, 128, 132, 149, 153, 156, 163, 167, 170, 177, 180, 183, 187, 194, 196 and 199. Details of 
the procedure were described elsewhere2. Briefly, after addition of internal standards and formic 
acid, 4 mL of plasma was extracted on a solid phase disk extraction cartridge. The extract was then 
cleaned on acidified silicagel and injected into a GC/MS operated in EI mode for PCBs and into a 
GC/MS operated in ECNI mode for OCPs.  
 
The Center of Analysis of Residues in Traces (CART, Liège, Belgium) analyzed 17 
polychlorinated dibenzo-dioxins and –furans (PCDDs and PCDFs) and 4 non-ortho PCBs. About 
40 mL of sample were spiked with a mixture of 13C-labelled standards and mixed with formic acid. 
This mixture was loaded on a Isolute C18 cartridge for extraction, followed by clean-up on a Power-
prep system. The purified extracts were then injected in a GC-HRMS3. 
 
Bio-analyses 
CALUX® analyses were performed by the Belgian Scientific Institute of Public Health 
(Brussels, Belgium). Ten mL of sample were extracted following a liquid-liquid extraction with a 
mixture of acetone/hexane, and purified on an acid silica column in series with an activated carbon 
column. After elution from the silica column, the extract was fractionated on the carbon column to 
yield dioxin and PCB fractions. Only the fraction containing PCDD/PCDFs was applied on mouse 
hepatoma H1L6.1 cells (XDS Inc., Durham, USA) for the determination of AhR activity. Results 
were expressed in pg TEQ/g lipids4.  
 
The estrogen activity of plasma samples was performed by XDS Inc.(Durham, USA) using 
the LUMI-CELLTM ER recombinant bioassay for estrogen screening. Samples were analyzed by 
mixing 5 µL of plasma with DMEM media then applying to the BG1Luc4E2 cells5.  
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Results and Discussion 
 
Perfluoroalkylated compounds  
Concentrations of PFOS, PFOA and PFHS in Belgian plasma are shown in Table 1a). Among 
the three fluorochemicals, PFOS was present at the highest concentration, followed by PFOA. The 
observed range of PFOS concentrations is similar to those reported by the OECD for Belgium1 (4.9 
- 22 ng/mL). Mean PFOS concentration in the plasma of Belgian donors was two times lower than 
those reported for US donors and four times higher than those found in Italy1. Concentration of 
PFOA in Belgian donors was similar to those observed in US donors (4.7 ng/mL) and higher than 
those reported for Italian donors. This seems to indicate that the pattern of exposure to 
perfluorochemicals in Belgium is similar to the US. 
No significant differences were found for the contamination with fluorochemicals between 
sexes. Moreover, those concentrations were not age-, BMI- and smoking habit-dependent. 
Concerning dietary habits, the PFOS concentration was significantly influenced by meat and milk 
consumption. These observations can be partially explained by the presence of some of these 
compounds in food. A US study has reported the presence of PFOS in a small number of milk and 
ground beef samples (data not published).  
 
Polychlorinated biphenyls congeners 
PCB concentrations found in the samples are summarized in Table 1a). The sum of the 7 
marker PCBs (PCB 28, 52, 101, 118, 138, 153, 180), sum of mono-ortho PCBs (PCB 105, 118, 156 
and 167), as well as the total sum of PCBs were calculated to make comparison easier. Since PCB 
18, 44, 66, 110, 128, 132 and 149 were found below the limit of quantification in all samples, they 
were not taken into consideration in calculations. The mean value observed for the 7 marker PCBs 
is similar to the mean value previously reported in Belgium by Fierens et. al6 and Koppen et. al7 
and higher than those obtained by Voorspoels et. al8. The difference with this latter can however be 
explained by the mean age of the sampled population, which is higher in the present study. As 
shown in Figure 1, the congener profile is dominated by the PCB 153, PCB 180 and PCB 138/163. 
These congeners represent more than 70% of the sum PCBs. Similar profiles were previously 
observed in Belgium and other countries, as well as in other human matrices (adipose tissue, breast 
milk or liver)6-9.  
The sum of the 7 marker PCBs, as well as the sum of mono-ortho PCBs and the sum PCBs, 
were positively correlated with the age of donors. No effect of BMI, smoke, gender or use of 
herbicides was detected. Following these results, the concentrations of PCBs were not significantly 
explained by any food consumption.  
 
Organochlorine pesticides 
From the 15 targeted OCPs, 8 compounds (α-HCH, o,p´-DDD, o,p´-DDE, o,p´-DDT, p,p´-
DDD, TC, CC and OCS) were not quantifiable in any of the 20 plasma samples. In all samples, 
p,p´-DDE was the major pesticide, followed by HCB, OxC and β-HCH. The predominance of p,p´-
DDE is in accordance with previous reports on OCPs in human samples8,10. The contamination 
level with p,p´-DDE is lower than the levels reported in Belgium by Koppen et al.7, but higher than 
those reported by Voorspoels et al.8. However, the important standard deviation observed in this 
study must be taken into account. The age of donors was the only determinant observed for β-
HCH, HCB and p,p´-DDE. 
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PCDD/F congeners 
When expressed in pg/g lipids, the profile of dioxins congeners was dominated by higher 
chlorinated compounds such OCDD, 1,2,3,4,5,7,8-HpCDD and 1,2,3,6,7,8-HxCDD. For furans, 
2,3,4,7,8-PeCDF was the most predominant congener, followed by 1,2,3,4,7,8-HxCDF and 
1,2,3,4,6,7,8-HpCDF. Similar to Sweden and Spain, PCDDs account for 90% of the total PCDD/F 
concentration10. The total PCDD/F levels observed in Belgium is in the same range of 
concentrations than those previously reported in Sweden11, Germany12, United States13 and lower 
than that reported in Spain11 and Portugal14. The profile of toxic equivalents reported as pg TEQ/L 
of plasma is presented in Figure 2. This pattern is dominated by 2,3,4,7,8 PeCDF and 1,2,3,7,8-
PeCDD, which represent together more than 70% of the total TEQ for PCDD/F. The mean TEQ-
value of 26.1 pg TEQ/g lipids is similar to those observed on larger sampling studies in 
Belgium15,16 and slightly higher than levels measured in Germany12, United States13 and Portugal14.  
The mean TEQ-value obtained by CALUX® bioassay is similar to the one given by GC-
HRMS when using human WHO-TEF. However, the comparison of  CALUX® and GC-HRMS 
results for each sample showed discrepancies ranging from -32 to 52.1 pg TEQ/g lipids. These 
differences are mainly explained by antagonistic and synergistic effects of other AhR ligands, such 
as PBDD/PBDFs, possibly present in the dioxin fraction analysed by CALUX®. Actually, those 
ligands are not completely identified.  
None of the possible studied factors by statistical treatment has shown a good correlation with 
the TEQ-values obtained by GC-HRMS or CALUX®. 
 
Estrogen activity 
None of the sample demonstrated any Estrogen activity over the detection limit of 34.67 
pg/µL β-Estradiol equivalent using the LUMI-CELLTM ER. 
 
Correlation between chemical compounds 
As previously observed7,15,17,18, significantly high correlations were found between Σ7 PCB 
markers, Σm-o PCBs, ΣPCBs, HCB, OxC, TN, PCDD/F TEQ-value, ΣPCDF and ΣcPCBs. β-HCH 
was also significantly correlated with Σm-o PCB, HCB and p,p´-DDE.  
The CALUX TEQ-value increases significantly as the PCDD/F TEQ value or the ΣPCDFs 
raises. This last observation indicates that the TEQ value is mainly dependent of the furans. This 
good correlation between CALUX and GC-HRMS TEQ-values were already several times reported 
for blood samples4,7. 
Concerning the fluorochemicals, no association was found with chlorinated compounds. 
However, the significant relationship between PFOS and PFOA suggest that the sources of 
exposures of those fluorochemicals are the same. 
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Table 1: Mean and median concentrations for organohalogenated compounds observed in the 20 
Belgian human plasma samples. 
 
A) Concentration (ng/mL) Concentration (ng/g lipid) 
  Mean (SD) Median [range] Mean (SD) Median [range] 
PFOS 15.66   (5.85) 17.20   [4.52 - 27.04] 2268.6  (941.6) 2215.1 [885.3 - 4629.5] 
PFOA 4.81   (2.99) 4.12     [1.08 - 12.84] 693.6    (450.3) 677.7   [239.5 - 2112.4] 
PFHS 1.26   (0.10) 1.25   [1.14 - 1.44] 171.8     (21.9) 167.5   [144.5 - 197.2] 
     
Σ 7 marker PCB  2.77   (1.48) 2.55    [0.65 - 5.71] 388.5    (226.9) 359.2     [72.6 - 938.7] 
Σ m-o PCBs 0.28   (0.16) 0.28    [0.08 - 0.58] 38.6       (23.4) 32.9     [8.7 - 83.8] 
Σ PCBs 3.61   (1.96) 3.54    [0.73 - 7.30] 504.8    (298.5) 468.6   [82.5 - 1197.4] 
          
γ-HCH 0.04   (0.02) 0.03    [0.025 - 0.12] 5.4      (2.7) 4.5          [3.1 - 14.6] 
β-HCH 0.17   (0.11) 0.15    [0.04 - 0.41] 23.1      (14.7) 16.7        [5.6 - 53.2] 
HCB 0.22   (0.14) 0.20    [0.06 - 0.51] 32.0      (19.6) 27.2        [7.3 - 66.9] 
OxC 0.16   (0.14) 0.11    [0.03 - 0.48] 22.3       (19.9) 15.8        [4.0 - 67.4] 
TN 0.06   (0.03) 0.06    [0.02 - 0.13] 8.4         (4.7) 7.6          [2.5 - 16.7] 
p,p´-DDE 2.74   (2.27) 2.48    [0.26 - 9.91] 365.0    (313.2) 344.2     [37.4 - 1390.3] 
p,p´-DDT 0.06   (0.02) 0.06    [0.05 - 0.09] 9.1         (2.5) 8.3          [6.0 - 13.5] 
          
B)  Concentration (pg/L) Concentration (pg/g lipid) 
  Mean (SD) Median [range] Mean (SD) Median [range] 
Σ n-o PCBs 1.22  (0.91) 0.81   [0.28 - 3.27] 176.0    (128.0) 132.6      [31.9 - 442.7] 
Σ PCDD 3.71   (4.49) 2.57   [0.24 - 21.29] 520.1    (606.4) 375.2     [34.9 - 2885.6] 
Σ PCDF 0.38  (0.24) 0.33   [0.10 - 0.86] 56.2       (37.4) 47.0       [13.2 - 144.3] 
Σ PCDD/F 4.09   (4.62) 3.27   [0.35 - 22.15] 576.2    (624.5) 454.3     [51.9 - 3002.1] 
     
C)  Concentration (pg TEQ/L) Concentration (pg TEQ/g lipid) 
  Mean (SD) Median [range] Mean (SD) Median [range] 
CALUX TEQ  187.8  (144.8) 151.0  [41.7-597.4] 26.9        (23.2) 19.9           [4.9 - 102.5] 
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Figure 2: PCDD/F profile in Belgian human plasma 
 
 
 
 
